BriSTAR Immunotech
Latest round
- Series C
Last raised
- Jul 2026
Total raised
- $67M
Investors
- 16
About BriSTAR Immunotech
Based in Beijing, China and founded in 2018, China Immunotech (Beijing) Biotechnology Co., trading as BriSTAR Immunotech, operates as a cellular immunotherapy developer that focuses on biopharmaceutical research and development. The company's founder is an immunologist and professor at Tsinghua University in Beijing, Xueqiang Zhao. The company cooperates with Lu Daopei Medical Group, Peking University First Hospital and Beijing Cancer Hospital. The company has filed nearly 100 invention patents globally and been granted more than 10 Chinese invention patents and PCT patents. The company provides cellular immunotherapy products for cancer and other diseases. The company developed Synthetic TCR and Antigen Receptor (STAR) and enTCR-T technologies platforms. The STAR technology can improve T cell expansion and reduce T cell depletion, and prevent tumor recurrence. The enTCR-T technology is used for complete antigen epitope prediction, multi-HLA tetramer preparation, high-throughput T cell receptor screening and identification. The cellular immunotherapy product pipelines focus on hematological tumors, solid tumors, and viral infections. The company generates revenue primarily through biotechnology research collaborations, licensing agreements, strategic partnerships, and technology development activities. In the future,the company will continue to adhere to independent innovation, continuously investing in R&D around its strategic directions of universal cell therapy and In vivo cell therapy, building a globally competitive cell therapy innovation platform, and providing patients with more safe, effective, and affordable treatment options.
Who invested in BriSTAR Immunotech
16 investors across 5 rounds
See all investors in BriSTAR Immunotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BriSTAR Immunotech
Who invested in BriSTAR Immunotech?
BriSTAR Immunotech has 16 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BriSTAR Immunotech raised?
BriSTAR Immunotech has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did BriSTAR Immunotech last raise money?
BriSTAR Immunotech's most recent round on record is a Series C, in Jul 2026.
What does BriSTAR Immunotech do?
Based in Beijing, China and founded in 2018, China Immunotech (Beijing) Biotechnology Co.
Where is BriSTAR Immunotech headquartered?
BriSTAR Immunotech is headquartered in Beijing, China.
Which VCs invest in companies like BriSTAR Immunotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at BriSTAR Immunotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like BriSTAR Immunotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.